A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Simon Peter Gampenrieder; R Angela; Gabriel Rinnerthaler; H Hackl; Markus Steiner; W Pulverer; A Weinhaeusel; E Klinglmayr; T Karl; S Ilic; Clemens Hufnagl; Cornelia Hauser-Kronberger; Alexander Egle; Richard Greil

doi:10.1158/1538-7445.SABCS18-P3-10-07

A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Simon Peter Gampenrieder
, R Angela
, Gabriel Rinnerthaler
, H Hackl
, Markus Steiner
, W Pulverer
, A Weinhaeusel
, E Klinglmayr
, T Karl
, S Ilic
, Clemens Hufnagl
, Cornelia Hauser-Kronberger
, Alexander Egle
, Richard Greil

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center
Institute of Pathology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	CANCER RESEARCH
Volume	79
Issue number	4
DOIs	https://doi.org/10.1158/1538-7445.SABCS18-P3-10-07
Publication status	Published - 2019
Event	San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 4 Dec 2018 → 8 Dec 2018

Access to Document

10.1158/1538-7445.SABCS18-P3-10-07

Cite this

Gampenrieder, S. P., Angela, R., Rinnerthaler, G., Hackl, H., Steiner, M., Pulverer, W., Weinhaeusel, A., Klinglmayr, E., Karl, T., Ilic, S., Hufnagl, C., Hauser-Kronberger, C., Egle, A., & Greil, R. (2019). A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. CANCER RESEARCH , 79(4). https://doi.org/10.1158/1538-7445.SABCS18-P3-10-07

Gampenrieder, Simon Peter ; Angela, R ; Rinnerthaler, Gabriel et al. / A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. In: CANCER RESEARCH 2019 ; Vol. 79, No. 4.

@article{64807fddc073448e85bf40b5fc90730f,

title = "A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial",

author = "Gampenrieder, \{Simon Peter\} and R Angela and Gabriel Rinnerthaler and H Hackl and Markus Steiner and W Pulverer and A Weinhaeusel and E Klinglmayr and T Karl and S Ilic and Clemens Hufnagl and Cornelia Hauser-Kronberger and Alexander Egle and Richard Greil",

year = "2019",

doi = "10.1158/1538-7445.SABCS18-P3-10-07",

language = "English",

volume = "79",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "4",

note = "San Antonio Breast Cancer Symposium ; Conference date: 04-12-2018 Through 08-12-2018",

}

Gampenrieder, SP, Angela, R, Rinnerthaler, G, Hackl, H, Steiner, M, Pulverer, W, Weinhaeusel, A, Klinglmayr, E, Karl, T, Ilic, S, Hufnagl, C, Hauser-Kronberger, C, Egle, A & Greil, R 2019, 'A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial', CANCER RESEARCH , vol. 79, no. 4. https://doi.org/10.1158/1538-7445.SABCS18-P3-10-07

A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. / Gampenrieder, Simon Peter; Angela, R; Rinnerthaler, Gabriel et al.
In: CANCER RESEARCH , Vol. 79, No. 4, 2019.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

AU - Gampenrieder, Simon Peter

AU - Angela, R

AU - Rinnerthaler, Gabriel

AU - Hackl, H

AU - Steiner, Markus

AU - Pulverer, W

AU - Weinhaeusel, A

AU - Klinglmayr, E

AU - Karl, T

AU - Ilic, S

AU - Hufnagl, Clemens

AU - Hauser-Kronberger, Cornelia

AU - Egle, Alexander

AU - Greil, Richard

PY - 2019

Y1 - 2019

U2 - 10.1158/1538-7445.SABCS18-P3-10-07

DO - 10.1158/1538-7445.SABCS18-P3-10-07

M3 - Abstract (Journal)

SN - 0008-5472

VL - 79

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 4

T2 - San Antonio Breast Cancer Symposium

Y2 - 4 December 2018 through 8 December 2018

ER -

Gampenrieder SP, Angela R, Rinnerthaler G, Hackl H, Steiner M, Pulverer W et al. A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial. CANCER RESEARCH . 2019;79(4). doi: 10.1158/1538-7445.SABCS18-P3-10-07